A chitosan-based nanosystem as pneumococcal vaccine delivery platform.


Journal

Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061

Informations de publication

Date de publication:
04 2021
Historique:
accepted: 26 01 2021
pubmed: 4 3 2021
medline: 15 12 2021
entrez: 3 3 2021
Statut: ppublish

Résumé

Chitosan-based nanosystems have been described as interesting tools for antigen delivery and for enhancing the immunogenicity of nasally administered vaccines. As a possible vaccine delivery method, the chemical conjugation of chitosan nanocapsules with the Streptococcus pneumoniae cell membrane protein PsaA (pneumococcal surface adhesin A) is suggested here. The antigen PsaA, common to all pneumococcus serotypes, is expected to improve its uptake by immune cells and to activate specific T cells, generating an adaptive immune response against pneumococcus. With this aim, chitosan nanocapsules with thiol-maleimide conjugation between the polymer (chitosan) and the antigen (PsaA) were designed to enable the surface presentation of PsaA for immune cell recognition. Spherical-shaped particles, with a size of 266 ± 32 nm, positive charge of +30 ± 1 mV, and good stability profiles in simulated nasal fluids (up to 24 h) were achieved. PsaA association rates were three times higher compared with nanocapsules without covalent polymer-protein conjugation. Cytotoxicity studies in cell culture media showed non-toxic effect under 150 µg/mL concentration of nanocapsules, and subsequent studies on the maturation of immature dendritic cells in the presence of antigen-conjugated nanocapsules displayed peripheral blood mononuclear cell activation and lymphocyte differentiation after their presentation by dendritic cells. Secretion of TNFα following exposure to nanocapsules and the ability of nanocapsules to activate CD4 and CD8 T lymphocytes had also been studied. Antigen loaded nanocarrier uptake and presentation by professional presenting cells.

Identifiants

pubmed: 33655441
doi: 10.1007/s13346-021-00928-3
pii: 10.1007/s13346-021-00928-3
doi:

Substances chimiques

Adhesins, Bacterial 0
Pneumococcal Vaccines 0
Chitosan 9012-76-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

581-597

Références

Pérez-Dorado I, Galan-Bartual S, Hermoso JA. Pneumococcal surface proteins: when the whole is greater than the sum of its parts. Mol Oral Microbiol. 2012;27:221–45.
pubmed: 22759309
Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, et al. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology. 2014;141:514–30.
pubmed: 24138116 pmcid: 3956426
Mohammadzadeh M, Mamishi S, Pourakbari B, Mahmoudi S. Recent approaches in whole cell pneumococcal vaccine development: a review study. Iran J Microbiol. 2017;9:381–8.
pubmed: 5825939
Leites A, Paula A, Argondizzo C, Esteves S, Jessouron E, Galler R, et al. Cloning and optimization of induction conditions for mature PsaA (pneumococcal surface adhesin A) expression in Escherichia coli and recombinant protein stability during long-term storage. Protein Expr Purif. 2011;78:38–47.
Bartual SG, Alcorlo M, Martínez-Caballero S, Molina R, Hermoso JA. Three-dimensional structures of Lipoproteins from Streptococcus pneumoniae and Staphylococcus aureus. Int J Med Microbiol. 2017;1–13.
Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW. Pneumococcal surface adhesin A (PsaA): a review. Crit Rev Microbiol. 2008;34:163–73.
pubmed: 18819028
Zheng Z, Diaz-Arévalo D, Guan H, Zeng M. Noninvasive vaccination against infectious diseases. Hum Vaccines Immunother. 2018;14:1717–33.
Almeida AJ, Florindo HF. Chapter 3.1. Nanocarriers Overcoming the Nasal Barriers: Physiological Considerations and Mechanistic Issues. 2012;117–32.
Calvo P, Remuñan-López C, Vila-Jato JL AM. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res. 1997;1431–1436
Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev. 2009;61:140–57.
pubmed: 19121350
Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release. 2003;87:187–98.
pubmed: 12618035
Slütter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J Drug Target. 2008;16:1–17.
pubmed: 18172815
Lewis KL, Reizis B. Dendritic cells: arbiters of immunity and immunological tolerance. Cold Spring Harb Perspect Biol. 2012;4:007401.
Cole J, Aberdein J, Jubrail J, Dockrell DH. The role of macrophages in the innate immune response to Streptococcus pneumoniae and Staphylococcus aureus: mechanisms and contrasts. Adv Microb Physiol. 2014;65:125–202.
pubmed: 25476766
Prego C, Torres D, Alonso MJ. The potential of chitosan for the oral administration of peptides. Expert Opin Drug Deliv. 2005;2:843–54.
pubmed: 16296782
Prego C, Torres D, Alonso MJ. Chitosan nanocapsules: a new carrier for nasal peptide delivery. J Drug Deliv Sci Technol. 2006;16:331–7.
Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62:3–11.
pubmed: 19800377
Shi GN, Zhang CN, Xu R, Niu JF, Song HJ, Zhang XY, et al. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. Biomaterials. 113:191–202.
Prasanna M, Soulard D, Camberlein E, Ruffier N, Lambert A, Trottein F, et al. Semisynthetic glycoconjugate based on dual role protein/PsaA as a pneumococcal vaccine. Eur J Pharm Sci. 2019;129:31–41.
pubmed: 30572107
Grenha A. Chitosan nanoparticles: a survey of preparation methods. J Drug Target. 2012;20:291–300.
González-Aramundiz JV, Presas E, Dalmau-Mena I, Martínez-Pulgarín S, Alonso C, Escribano JM, et al. Rational design of protamine nanocapsules as antigen delivery carriers. J Control Release. 2017;245:62–9.
pubmed: 27856263
Shen J, Burgess DJ. In vitro dissolution testing strategies for nanoparticulate drug delivery systems: recent developments and challenges. Drug Deliv Transl Res. 2013;3:409–15.
pubmed: 24069580 pmcid: 3779615
Posch W, Lass-Flörl C, Wilflingseder D. Generation of human monocyte-derived dendritic cells from whole blood. J Vis Exp. 2016;2016:2–7.
Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.
pubmed: 10837075
Kowalewicz-Kulbat M, Ograczyk E, Krawczyk K, Rudnicka W, Fol M. Type of monocyte immunomagnetic separation affects the morphology of monocyte-derived dendritic cells, as investigated by scanning electron microscopy. J Immunol Methods. 2016;439:79–82.
pubmed: 27746164
Hu X, Zheng W, Wang L, Wan N, Wang B, Li W, et al. The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide: pidotimod (PTD). Hum Vaccines Immunother. 2012;8:1250–8.
Lecoeur H, De Oliveira-Pinto LM, Gougeon ML. Multiparametric flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay. J Immunol Methods. 2002;265:81–96.
pubmed: 12072180
Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccines Immunother. 2016;12:383–92.
Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol. 2006;32:139–53.
pubmed: 16893751
Whaley MJ, Sampson JS, Johnson SE, Rajam G, Stinson-Parks A, Holder P, et al. Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model. Vaccine. 2010;28:3071–5.
pubmed: 20206671
Derksen JTP, Scherphof GL. An improved method for the covalent coupling of proteins to liposomes. BBA Biomembranes. 1985;814:151–5.
Scaria PV, Chen B, Rowe CG, Jones DS, Barnafo E, Fischer ER, et al. Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity. PLoS One. 2017;12:1–19.
Couñago RM, Ween MP, Begg SL, Bajaj M, Zuegg J, O’Mara ML, et al. Imperfect coordination chemistry facilitates metal ion release in the Psa permease. Nat Chem Biol. 2014;10:35–41.
pubmed: 24212134
Sahoo D, Sahoo S, Mohanty P, Sasmal S, Nayak PL. Chitosan: a new versatile bio-polymer for various applications. Des Monomers Polym. 2009;12:377–404.
Matsumoto M, Udomsinprasert W, Laengee P, Honsawek S, Patarakul K, Chirachanchai S. A water-based chitosan-maleimide precursor for bioconjugation: an example of a rapid pathway for an in situ injectable adhesive gel. Macromol Rapid Commun. 2016;37:1618–22.
pubmed: 27461078
Martínez-Jothar L, Doulkeridou S, Schiffelers RM, Sastre Torano J, Oliveira S, van Nostrum CF, et al. Insights into maleimide-thiol conjugation chemistry: conditions for efficient surface functionalization of nanoparticles for receptor targeting. J Control Release. 2018;282:101–9.
pubmed: 29526739
Malhotra M, Tomaro-Duchesneau C, Saha S, Kahouli I, Prakash S. Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. Int J Nanomedicine. 2013;8:2041–52.
pubmed: 23723699 pmcid: 3666663
Kumirska J, Czerwicka M, Kaczyński Z, Bychowska A, Brzozowski K, Thöming J, et al. Application of spectroscopic methods for structural analysis of chitin and chitosan. Mar Drugs. 2010;8:1567–636.
pubmed: 20559489 pmcid: 2885081
Esquivel R, Juárez J, Almada M, Ibarra J, Valdez MA. Synthesis and characterization of new thiolated chitosan nanoparticles obtained by ionic gelation method. Int J Polym Sci. 2015;2015:1–18.
Goulart C, Rodriguez D, Kanno AI, Silva JLSC, Leite LCC. Early pneumococcal clearance in mice induced by systemic immunization with recombinant BCG PspA-PdT prime and protein boost correlates with cellular and humoral immune response in bronchoalveolar fluids (BALF). Vaccine X; 2020;4:100049.
Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother. 2004;58:168–72.
pubmed: 15082339
Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, et al. Nanoemulsion: concepts, development and applications in drug delivery. J Control Release. 2017;252:28–49.
pubmed: 28279798
Goycoolea FM, Valle-Gallego A, Stefani R, Menchicchi B, David L, Rochas C, et al. Chitosan-based nanocapsules: physical characterization, stability in biological media and capsaicin encapsulation. Colloid Polym Sci. 2012;290:1423–34.
Calvo P, Alonso MJ, Sur C. Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polym Sci. 1997;275:46–53.
Gradauer K, Vonach C, Leitinger G, Kolb D, Fröhlich E, Roblegg E, et al. Chemical coupling of thiolated chitosan to preformed liposomes improves mucoadhesive properties. Int J Nanomedicine. 2012;7:2523–34.
pubmed: 22679365 pmcid: 3367495
Maruyama CR, Guilger M, Pascoli M, Bileshy-José N, Abhilash PC, Fraceto LF, et al. Nanoparticles based on chitosan as carriers for the combined herbicides imazapic and imazapyr. Sci Rep. 2016;6:19768.
pubmed: 26813942 pmcid: 4728438
Shrestha S, Wang B, Dutta P. Nanoparticle processing: understanding and controlling aggregation. Adv Colloid Interface Sci. 2020;279:102–62.
González-Aramundiz JV, Peleteiro M, González-Fernández Á, Alonso MJ, Csaba NS. Protamine nanocapsules for the development of thermostable adjuvanted nanovaccines. Mol Pharm. 2018;15:5653–64.
pubmed: 30375877
Tuoriniemi J, Johnsson ACJH, Holmberg JP, Gustafsson S, Gallego-Urrea JA, Olsson E, et al. Intermethod comparison of the particle size distributions of colloidal silica nanoparticles. Sci Technol Adv Mater. 2014;15.
Menchicchi B, Fuenzalida JP, Bobbili KB, Hensel A, Swamy MJ, Goycoolea FM. Structure of chitosan determines its interactions with mucin. Biomacromol. 2014;15:3550–8.
Collado-González M, Espinosa YG, Goycoolea FM. Interaction between chitosan and mucin: fundamentals and applications. Biomimetics. 2019;4:1–20.
He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI. High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem. 2010;399:141–3.
pubmed: 19995543
Raskin MM, Schlachet I, Sosnik A. Mucoadhesive nanogels by ionotropic crosslinking of chitosan-g-oligo(NiPAam) polymeric micelles as novel drug nanocarriers. Nanomedicine. 2016;11:217–33.
pubmed: 26786232
Szymańska E, Winnicka K. Stability of chitosan - a challenge for pharmaceutical and biomedical applications. Mar Drugs. 2015;13:1819–46.
pubmed: 25837983 pmcid: 4413189
Tonglairoum P, Brannigan RP, Opanasopit P, Khutoryanskiy VV. Maleimide-bearing nanogels as novel mucoadhesive materials for drug delivery. J Mater Chem B. 2016;4:6581–7.
pubmed: 32263701
Kaldybekov DB, Tonglairoum P, Opanasopit P, Khutoryanskiy VV. Mucoadhesive maleimide-functionalised liposomes for drug delivery to urinary bladder. Eur J Pharm Sci. 2018;111:83–90.
pubmed: 28958893
Tzankova V, Gorinova C, Kondeva-Burdina M, Simeonova R, Philipov S, Konstantinov S, et al. In vitro and in vivo toxicity evaluation of cationic PDMAEMA-PCL-PDMAEMA micelles as a carrier of curcumin. Food Chem Toxicol. 2016;97:1–10.
pubmed: 27565559
Mellman I, Steinman RM. Minireview Dendritic Cells: Specialized and Regulated Antigen Processing Machines cells are adept at endocytosis and express relatively low levels of surface MHC class I and II products and costimu-latory molecules (e.g., CD86). Abundant MHC class II mol. Cell. 2001;106:255–8.
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.
pubmed: 9521319
Al-Ashmawy GMZ. Dendritic Cell Subsets, Maturation and Function. Dendritic Cells. InTech; 2018.
Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005;106:2375–81.
pubmed: 15947091 pmcid: 1895261
Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9:1069–77.
pubmed: 12232795
Caulfield MJ. Endotoxin-induced T lymphocyte S N Vogel, M L Hilfiker and M J Caulfield. J Immunol. 1983;130:1774–9.
pubmed: 6601137
Craig A, Mai J, Cai S, Jeyaseelan S. Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun. 2009;77:568–75.
pubmed: 19015252
Dzopalic T, Rajkovic I, Dragicevic A, Colic M. The response of human dendritic cells to co-ligation of pattern-recognition receptors. Immunol Res. 2012;52:20–33.
pubmed: 22392051
Peleteiro M, Presas E, González-Aramundiz JV, Sánchez-Correa B, Simón-Vázquez R, Csaba N, et al. Polymeric nanocapsules for vaccine delivery: Influence of the polymeric shell on the interaction with the immune system. Front Immunol. 2018;9.

Auteurs

Sandra Robla (S)

Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, A Coruña, Spain.
Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, A Coruña, Spain.

Maruthi Prasanna (M)

Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, A Coruña, Spain.
Unit Function & Protein Engineering UMR CNRS 6286, University of Nantes, Nantes Cedex, France.

Rubén Varela-Calviño (R)

Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, A Coruña, Spain.

Cyrille Grandjean (C)

Unit Function & Protein Engineering UMR CNRS 6286, University of Nantes, Nantes Cedex, France.

Noemi Csaba (N)

Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, A Coruña, Spain. noemi.csaba@usc.es.
Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, A Coruña, Spain. noemi.csaba@usc.es.

Articles similaires

Animals Humans TOR Serine-Threonine Kinases Lupus Erythematosus, Systemic Arthritis, Rheumatoid
Porphyromonas gingivalis MicroRNAs Humans Periodontitis Adhesins, Bacterial

Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.

Prashant Kesharwani, Kratika Halwai, Saurav Kumar Jha et al.
1.00
Chitosan Humans Folic Acid Nanoparticles Drug Carriers
Animals Phascolarctidae Retroviridae Infections Retroviridae Biomarkers

Classifications MeSH